Chimeric antigen receptor (CAR) T cells show remarkable therapeutic effects in some
hematological malignancies. However, CAR T cells can also cause life-threatening side …

As regulatory T cells (Tregs) play a fundamental role in immune homeostasis their adoptive
transfer emerged as a promising treatment strategy for inflammation-related diseases …

CAR-modified T cells show impressive results in clinical trials. However, cytokine release
syndrome and “on-target, off-tumor” reactions represent most concerning side effects. To …

Adoptive transfer of engineered NK cells, one of clinical approaches to fight cancer, is
gaining great interest in the last decade. However, the development of new strategies is …

The traditional “one treatment fits all” paradigm disregards the heterogeneity between
cancer patients, and within a particular tumor, thus limit the success of common treatments …

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most
patients eventually relapse or become refractory to current treatments. Although the …

Recent progress in cancer immunotherapy has resulted in complete responses in patients
refractory to current standard cancer therapies. However, due to tumor heterogeneity and …

Conventional treatment for cancer routinely includes surgical resection and some
combination of chemotherapy and radiation. These approaches are frequently accompanied …

The clinical application of immune effector cells genetically modified to express chimeric
antigen receptors (CARs) has shown impressive results including complete remissions of …

In spite of specific immune effector mechanisms raised against tumor cells, there are
mechanisms employed by the tumor cells to keep them away from immune recognition and …